Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025CancersOpen Access

Integration of Next-Generation Sequencing in Measurable Residual Disease Monitoring in Acute Myeloid Leukemia and Myelodysplastic Neoplasm

View Full Paper
Ask AI
Bookmark
Share

Authors

ECElena CrisàIDIrene DogliottiGLGiuseppe Lia

Discussion

Loading...

Member takes

Overview

Prospective study shows improved relapse-free survival using NGS and multiparameter flow cytometry in AML and MDS patients.

Key Points

  • NGS identified somatic mutations in 95% of patients with AML/MDS at diagnosis, supporting its critical role in monitoring.
  • Persistence of mutations during complete remission was linked with reduced overall survival, with a median of 8 months relapse-free survival.
  • Combining NGS with multiparameter flow cytometry allowed for better risk stratification among patients, enhancing treatment decisions.
  • NGS and MFC variables emerged as independent predictors of relapse-free survival, indicating their importance in clinical settings.

Cite This Study

Crisà et al. (2025) studied this question.

synapsesocial.com/papers/68c239a3b210217d6477d853https://doi.org/10.3390/cancers17172874
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Monitoring of measurable residual disease by next‐generation sequencing in patients with acute myeloid leukaemia2025 · 5 citations
  2. 2A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia2025 · 2 citations
  3. 3Impact of minimal residual disease and next generation sequencing discordance in AML following induction with hypomethylating agent + venetoclax.2025
  4. 4Comparative evaluation of NGS-based MRD detection in AML using longitudinal matched bone marrow and blood samples2025
  5. 5Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.2025